...
首页> 外文期刊>Bulletin of experimental biology and medicine >Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.
【24h】

Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.

机译:卵巢肿瘤患者的肿瘤和血清中的基质金属蛋白酶2、7和9和金属蛋白酶-1组织抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

The content of matrix metalloproteinases 7 and 9 was significantly increased, while the content of metalloproteinase 2 was reduced in ovarian cancer tissue compared to benign tumors. In blood serum from patients with ovarian cancer, the concentrations of matrix metalloproteinases 7 and 9 and their type 1 tissue inhibitor were significantly elevated, while the concentration of matrix metalloproteinase 2 was reduced compared to the corresponding parameters in healthy women. After chemotherapy, tissue and serum concentrations of metalloproteinases and their inhibitor in patients practically returned to normal. A significant positive correlation between serum levels of matrix metalloproteinases 7 and 9 and tissue inhibitor of metalloproteinases-1 in patients with ovarian cancer and the size of primary tumor (ultrasound examination) and a positive correlation between these parameters and the concentration of classical ovarian cancer marker CA-125 were demonstrated.
机译:与良性肿瘤相比,卵巢癌组织中基质金属蛋白酶7和9的含量显着增加,而金属蛋白酶2的含量降低。与健康女性的相应参数相比,在卵巢癌患者的血清中,基质金属蛋白酶7和9及其1型组织抑制剂的浓度显着升高,而基质金属蛋白酶2的浓度则降低。化疗后,患者体内金属蛋白酶及其抑制剂的组织和血清浓度实际上恢复了正常。卵巢癌患者血清中金属蛋白酶7和9和金属蛋白酶-1组织抑制剂的血清水平与原发肿瘤大小(超声检查)之间呈显着正相关,并且这些参数与经典卵巢癌标志物浓度呈正相关证明了CA-125。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号